MA43716A - Anticorps anti-tnf et fragments fonctionnels de ceux-ci - Google Patents
Anticorps anti-tnf et fragments fonctionnels de ceux-ciInfo
- Publication number
- MA43716A MA43716A MA043716A MA43716A MA43716A MA 43716 A MA43716 A MA 43716A MA 043716 A MA043716 A MA 043716A MA 43716 A MA43716 A MA 43716A MA 43716 A MA43716 A MA 43716A
- Authority
- MA
- Morocco
- Prior art keywords
- functional fragments
- tnf antibodies
- tnf
- antibodies
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16160923 | 2016-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43716A true MA43716A (fr) | 2018-11-28 |
Family
ID=55542582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043716A MA43716A (fr) | 2016-03-17 | 2017-03-16 | Anticorps anti-tnf et fragments fonctionnels de ceux-ci |
Country Status (11)
Country | Link |
---|---|
US (1) | US10759852B2 (fr) |
EP (1) | EP3430042B1 (fr) |
JP (1) | JP7184746B2 (fr) |
KR (1) | KR102449711B1 (fr) |
CN (1) | CN109071649B (fr) |
BR (1) | BR112018017165A2 (fr) |
CA (1) | CA3011502A1 (fr) |
EA (1) | EA039201B1 (fr) |
IL (1) | IL261098A (fr) |
MA (1) | MA43716A (fr) |
WO (1) | WO2017158084A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108884156B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
EP3219727B1 (fr) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
DK3219726T3 (da) | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
WO2020114616A1 (fr) | 2018-12-07 | 2020-06-11 | Tillotts Pharma Ag | Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
EP0519596B1 (fr) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | Procédé pour réduire l'immunogénicité des domaines variables d'anticorps |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
WO1993011236A1 (fr) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production d'anticorps anti-auto-antigenes a partir de repertoires de segments d'anticorps affiches sur phage |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (fr) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Anticorps humains derives de xeno-souris immunisees |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
WO1998024893A2 (fr) | 1996-12-03 | 1998-06-11 | Abgenix, Inc. | MAMMIFERES TRANSGENIQUES POSSEDANT DES LOCI DE GENES D'IMMUNOGLOBULINE D'ORIGINE HUMAINE, DOTES DE REGIONS VH ET Vλ, ET ANTICORPS PRODUITS A PARTIR DE TELS MAMMIFERES |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
US7431927B2 (en) * | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
AU2006255415B2 (en) | 2005-06-07 | 2011-10-06 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
ES2861592T3 (es) | 2008-06-25 | 2021-10-06 | Novartis Ag | Anticuerpos estables y solubles que inhiben el TNF |
CN102164958A (zh) | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
JP5579713B2 (ja) | 2008-07-10 | 2014-08-27 | エスバテック − ア ノバルティス カンパニー エルエルシー | 高分子の送達増強のための方法および組成物 |
EP2593476A2 (fr) * | 2010-07-16 | 2013-05-22 | Ablynx N.V. | Molécules de liaison à un antigène à domaine unique modifiées et leurs utilisations |
US9096669B2 (en) * | 2010-09-30 | 2015-08-04 | Chengdu Kanghong Biotechnologies Co., Ltd. | Humanized anti-TNF-α antibody and antigen-binding fragment (Fab) thereof and use of the same |
AU2014301629B2 (en) | 2013-06-26 | 2020-02-06 | Numab Therapeutics AG | Novel antibody frameworks |
US9416197B2 (en) | 2013-11-01 | 2016-08-16 | Ibc Pharmaceuticals, Inc. | Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease |
WO2015144852A1 (fr) * | 2014-03-26 | 2015-10-01 | Delenex Therapeutics Ag | Éléments de liaison dirigés contre tnf alpha |
DK3219726T3 (da) | 2016-03-17 | 2020-12-07 | Tillotts Pharma Ag | Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf |
EP3219727B1 (fr) | 2016-03-17 | 2020-12-16 | Tillotts Pharma AG | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci |
CN108884156B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
-
2017
- 2017-03-16 EA EA201892090A patent/EA039201B1/ru unknown
- 2017-03-16 CN CN201780012616.2A patent/CN109071649B/zh active Active
- 2017-03-16 WO PCT/EP2017/056227 patent/WO2017158084A1/fr active Application Filing
- 2017-03-16 CA CA3011502A patent/CA3011502A1/fr active Pending
- 2017-03-16 MA MA043716A patent/MA43716A/fr unknown
- 2017-03-16 US US16/085,565 patent/US10759852B2/en active Active
- 2017-03-16 JP JP2019500012A patent/JP7184746B2/ja active Active
- 2017-03-16 KR KR1020187024075A patent/KR102449711B1/ko active IP Right Grant
- 2017-03-16 BR BR112018017165A patent/BR112018017165A2/pt unknown
- 2017-03-16 EP EP17710746.3A patent/EP3430042B1/fr active Active
-
2018
- 2018-08-10 IL IL261098A patent/IL261098A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN109071649A (zh) | 2018-12-21 |
JP7184746B2 (ja) | 2022-12-06 |
US20190194310A1 (en) | 2019-06-27 |
EA201892090A1 (ru) | 2019-02-28 |
IL261098A (en) | 2018-10-31 |
EP3430042A1 (fr) | 2019-01-23 |
JP2019512267A (ja) | 2019-05-16 |
EP3430042B1 (fr) | 2023-05-24 |
CA3011502A1 (fr) | 2017-09-21 |
EA039201B1 (ru) | 2021-12-16 |
BR112018017165A2 (pt) | 2019-01-02 |
KR102449711B1 (ko) | 2022-09-30 |
KR20180117108A (ko) | 2018-10-26 |
CN109071649B (zh) | 2021-10-01 |
WO2017158084A1 (fr) | 2017-09-21 |
US10759852B2 (en) | 2020-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
IL272274A (en) | Antibodies 4H-7B methods for their use | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
DK3618863T3 (da) | Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
DK3601358T3 (da) | Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf | |
SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
DK3653221T3 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
MA43717A (fr) | Anticorps anti-tnf et fragments fonctionnels de ceux-ci | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
MA49726A (fr) | Formulation d'anticorps anti-cgrp | |
EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
MA43738A (fr) | Anticorps anti-tnfalpha et leurs fragments fonctionnels | |
IL264528B1 (en) | fcrn antibodies and methods of using them | |
ZA202003695B (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
IL267673A (en) | Broad neutralizing antibodies against hiv-1 and methods of using them | |
CR20180296A (es) | ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO | |
IL265957A (en) | Anti-c1s antibodies and methods of using them | |
MA43715A (fr) | Anticorps anti-tnf et fragments fonctionnels correspondants |